Gla. Bird et al., RANDOMIZED CONTROLLED DOUBLE-BLIND TRIAL OF THE CALCIUM-CHANNEL ANTAGONIST AMLODIPINE IN THE TREATMENT OF ACUTE ALCOHOLIC HEPATITIS, Journal of hepatology, 28(2), 1998, pp. 194-198
Background / Aims: Calcium channel blockers have a hepatoprotective ac
tion in animal models of alcohol-induced liver injury but their effect
in alcoholic liver disease in humans has not been previously investig
ated. We have conducted a randomised, placebo-controlled trial to inve
stigate the possible benefit of the calcium channel blocker amlodipine
in term of 4-week survival in hospitalised patients with severe acute
alcoholic hepatitis. Methods: Sixty-two patients with acute alcoholic
hepatitis were randomised to receive 5-10 mg amlodipine each day for
1 year or an identical capsule containing placebo. In 36 (58%), acute
alcoholic hepatitis was confirmed on biopsy and in the remainder on cl
inical and laboratory criteria. There were no statistically significan
t differences in clinical characteristics and disease severity in the
treated and placebo groups. Results: Of the 32 patients receiving amlo
dipine, there were six deaths (19%) in the first 4 weeks compared with
seven (23%) of the placebo patients (p=0.329). Causes of death were s
imilar in the amlodipine and control groups, with liver failure predom
inant. Analysis by the Cox proportional hazards model after adjustment
for other prognostic factors showed survival was not significantly in
fluenced by active treatment (p=0.07). One patient in each group was w
ithdrawn because of the development of hypotension, but this did not r
ecur on reintroduction of the capsules. Conclusions: This study shows
that calcium channel blockers are well tolerated with few side effects
in advanced alcoholic liver disease, but there is no conclusive evide
nce from this study that calcium channel blockers are helpful in the t
reatment of alcoholic hepatitis.